Mariëtte J Agterof

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer et al. · The Lancet Oncology · 2017 · 157 citations

Medicine, Clinical Trials, Gynecology +10

Out of hospital treatment of acute pulmonary embolism in patients with a low NT‐proBNP level

Mariëtte J Agterof, Roger E. G. Schutgens, Repke J. Snijder et al. · Journal of Thrombosis and Haemostasis · 2010 · 135 citations · Full text

Pulmonary Embolism, Critical Care Medicine, Thrombosis +8

Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy

Tam Binh V. Bui, Desirée M. T. Burgers, Mariëtte J Agterof et al. · Breast Cancer Basic and Clinical Research · 2019 · 40 citations · Full text

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst et al. · The Lancet Oncology · 2024 · 36 citations · Full text

Neoadjuvant Chemotherapy Duration, Breast Oncology, Medical Imaging +10

Bortezomib-Induced Skin Lesions

Mariëtte J Agterof, Douwe H. Biesma · New England Journal of Medicine · 2005 · 35 citations

Vasculitis, Immunology, Pathology +16